TNG917

TNG917 (3-30 mg/kg, p.o.; once daily) inhibits the growth of HT29 human colon cancer xenografts in immunodeficient NOG mice, with tumor growth inhibition rates of approximately 50% and 84% observed in the 10 and 30 mg/kg dose groups, respectively^[1].
TNG917 (10-100 mg/kg, p.o.; once daily for 5 consecutive days) exhibits dose-dependent plasma exposure in female C57BL/6 mice bearing MC38 tumors, and reduces H3K9me2 levels in tumor tissues at 2 and 8 h after the final administration^[1].
Combination treatment with TNG917 (3, 30 mg/kg, p.o.; once daily for 6 consecutive days) and Pembrolizumab (HY-P9902A) (10 mg/kg, i.p.; once weekly for a total of 3 times) increases the infiltration of total T cells, CD8⁺ T cells, CD4⁺ T cells and M1 macrophages, and reduces M2 macrophages within CT26 tumors^[1].
Combination treatment with TNG917 (30 mg/kg, p.o.) and Pembrolizumab (10 mg/kg, i.p.) induces chemokines such as Ccl8, Ccl5 and Ccl3, as well as interferon-stimulated gene-related signals in CT26 tumor tissues^[1].